Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower ...

Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...

The GLP-1 agonist was the first drug in the partnership ... recently approved for diabetes and in late-stage testing in obesity. For now, Rybelsus will be in Pfizer and Sosei Heptares' sights ...

Pfizer executives are still bullish on the opportunity for its own obesity and diabetes drugs under development, eyeing a potential opening for oral versions and an improved safet ...

US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Meanwhile, Wall Street has a new fixation: diabetes and weight-loss drugs pioneered by Eli Lilly and Novo Nordisk. Pfizer has yet to distinguish itself in the increasingly competitive race for ...

Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain hemophilia patients. The drug will be marketed under the trade name Hympavzi.

On that note, time to get cracking. Best of luck, and do keep in touch. … The number of active drug shortages is 277 in this ...

Confounding data from a Pfizer clinical trial have rattled the ... but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such ...

Pfizer (PFE) offered up some more details ... Incretin drugs are a class of diabetes and obesity medications that mimic hormones that regulate blood sugar and suppresses appetite.